Core Insights - Visionary Holdings Inc. has appointed Ms. Wenxuan Cai as the CEO of its subsidiary, Visionary Health Technology Group Limited in Hong Kong, effective immediately [1] - The company has established a new wholly owned subsidiary in Nanjing, China, focusing on sales execution and market development, marking a shift from strategic positioning to active revenue generation [2] Leadership and Market Strategy - Ms. Cai brings nearly two decades of experience in market expansion and sales organization building, particularly in the healthcare sector, and will focus on enhancing sales infrastructure and execution [3][8] - The Nanjing entity will serve as a frontline commercial platform for regional sales operations, completing a fully integrated commercial structure alongside the Hong Kong platform [4] Commercialization Efforts - The company has transitioned from conceptual planning to operational commercialization, with a strong emphasis on building high-performance sales teams and translating market strategies into commercial results [5][6] - Recent milestones include strategic entry into cellular rejuvenation and aesthetic treatment markets, completion of global technology licensing, and the launch of a diversified product portfolio [9] Growth Potential - With leadership, products, and sales infrastructure aligned, the company is well-positioned to capitalize on the growing demand for advanced cellular-based and aesthetic solutions across Asia [7]

[música] Os quería pedir antes que nada un favor a todos. Imaginad en vuestras cabezas la siguiente escena. Va saber que es muy sencilla.Es un día cualquiera. Suena el despertador. Son las 8 de la mañana.Te levantas. ¿Todavía te arrepientes de las últimas cervezas que te tomaste anoche. Pero te pones rápidamente tus mallas, tus zapatillas de correr y sales como cada mañana a correr alrededor, 5 km alrededor de tu casa.Vuelves, te duchas, desayunas y te pones a contestar emails que te han quedado en la bande ...

Core Insights - Klotho Neurosciences plans to acquire assets from Turn Biotechnologies, focusing on longevity therapeutics and cellular reprogramming [1][2] - The acquisition includes Turn's Epigenetic Reprogramming of Age (ERA) platform and the eTurna RNA delivery system, developed at Stanford University [2] - The deal is contingent upon due diligence, a definitive agreement, and typical closing conditions [1] Technology and Applications - The technologies aim to restore tissue function and rejuvenate somatic cells, with potential applications in ophthalmology, dermatology, osteoarthritis, muscle health, immunology, and amyotrophic lateral sclerosis (ALS) [3] - Klotho's acquisition includes a partnership with a South Korean pharmaceutical company, potentially valued at up to $300 million [3] Strategic Implications - The collaboration highlights commercial interest in Turn's platform and its broad technological potential [4] - Post-acquisition, Klotho plans to rebrand to reflect its expanded mission and therapeutic capabilities [4] - Key personnel from Turn Biotechnologies will join Klotho's management and R&D teams after the transaction [4] Leadership Perspective - Klotho's CEO emphasized the transformative nature of the acquisition, linking the Klotho gene to anti-aging and neuroprotection [5] - The integration of Turn's ERA technology, which utilizes six RNA molecules, aims to enhance cellular rejuvenation capabilities [6]